-
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Amarillo, Dallas, Houston, San Antonio
-
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin, Dallas
-
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Dallas, Houston, Tyler
-
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT06999187 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin, Dallas, San Antonio
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston, Irving
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Dallas, Fort Worth, Houston, Richardson
-
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
NCT07705334 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston, San Antonio
-
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Austin, San Antonio
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
NCT03740256 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
Comprehensive Outcomes for After Cancer Health
NCT05349227 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT07517198 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Fort Worth
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston, San Antonio
-
IDOV-Immune for Advanced Solid Tumors
NCT06910657 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston, San Antonio
-
IKS014 in Advanced Solid Tumors That Express HER2
NCT05872295 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Fort Worth
-
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female)
· Texas: Houston
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Houston
-
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06047379 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Dallas
-
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211 ·
Phase: Phase 2 ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· Texas: Houston
-
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Dallas, El Paso, San Antonio, The Woodlands
-
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Dallas, Houston
-
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Texas: Dallas
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
NCT07432633 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Texas: Dallas